CA2373814A1 - Composes et methodes de regulation de l'apoptose, et methodes d'elaboration et de criblage de composes regulateurs de l'apoptose - Google Patents

Composes et methodes de regulation de l'apoptose, et methodes d'elaboration et de criblage de composes regulateurs de l'apoptose Download PDF

Info

Publication number
CA2373814A1
CA2373814A1 CA002373814A CA2373814A CA2373814A1 CA 2373814 A1 CA2373814 A1 CA 2373814A1 CA 002373814 A CA002373814 A CA 002373814A CA 2373814 A CA2373814 A CA 2373814A CA 2373814 A1 CA2373814 A1 CA 2373814A1
Authority
CA
Canada
Prior art keywords
bad
seq
fragment
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373814A
Other languages
English (en)
Inventor
Xiao-Mai Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apoptosis Technology Inc
Original Assignee
Apoptosis Technology, Inc.
Xiao-Mai Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoptosis Technology, Inc., Xiao-Mai Zhou filed Critical Apoptosis Technology, Inc.
Publication of CA2373814A1 publication Critical patent/CA2373814A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
CA002373814A 1999-05-28 2000-05-30 Composes et methodes de regulation de l'apoptose, et methodes d'elaboration et de criblage de composes regulateurs de l'apoptose Abandoned CA2373814A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13678399P 1999-05-28 1999-05-28
US60/136,783 1999-05-28
PCT/US2000/011864 WO2001010888A1 (fr) 1999-05-28 2000-05-30 Composes et methodes de regulation de l'apoptose, et methodes d'elaboration et de criblage de composes regulateurs de l'apoptose

Publications (1)

Publication Number Publication Date
CA2373814A1 true CA2373814A1 (fr) 2001-02-15

Family

ID=22474341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373814A Abandoned CA2373814A1 (fr) 1999-05-28 2000-05-30 Composes et methodes de regulation de l'apoptose, et methodes d'elaboration et de criblage de composes regulateurs de l'apoptose

Country Status (5)

Country Link
EP (1) EP1181306A4 (fr)
JP (1) JP2003506071A (fr)
AU (1) AU765983B2 (fr)
CA (1) CA2373814A1 (fr)
WO (1) WO2001010888A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6933127B2 (en) 2001-07-05 2005-08-23 Eucro European Contract Research Gmbh & Co. Kg Substrate for PP2C
EP1273654A1 (fr) * 2001-07-05 2003-01-08 Schering Aktiengesellschaft BAD comme substrat pour PPC2
JPWO2003018058A1 (ja) * 2001-08-22 2004-12-09 横田　充弘 心筋細胞のアポトーシス抑制剤
WO2003042239A1 (fr) * 2001-11-12 2003-05-22 Stichting Sanquin Bloedvoorziening Peptides inhibant la signalisation des gtpases de type ras
DK1343013T3 (da) * 2002-03-07 2006-08-21 Pasteur Institut Fremgangsmåder til screening af forbindelser der modulerer apoptose, forbindelser der er identificeret ved fremgangsmåderne, og anvendelse af forbindelserne som terapeutiske midler
WO2003082322A1 (fr) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. Méthode de modulation d'activité cellulaire
JP2004018524A (ja) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg 動脈硬化症を処置するための方法
EP1661912A1 (fr) * 2004-11-29 2006-05-31 Xigen S.A. Protéine de fusion comprenant un domaine BH3 d'une protéine BH3-only
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007035494A2 (fr) * 2005-09-16 2007-03-29 The Regents Of The University Of California Induction de l'expression de puma permettant de reduire l'inflammation articulaire dans le traitement de l'arthrite
AU2008229648A1 (en) * 2007-03-20 2008-09-25 The Walter And Eliza Hall Institute Of Medical Research Method of screening
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
CA2807036C (fr) 2010-10-14 2018-01-16 Xigen S.A. Utilisation d'inhibiteurs peptidiques, aptes a penetrer dans les cellules, de la voie de transduction du signal jnk pour le traitement de maladies oculaires inflammatoires chroniques ou non-chroniques
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
WO2014206563A2 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de diverses maladies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965703A (en) * 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use

Also Published As

Publication number Publication date
EP1181306A1 (fr) 2002-02-27
WO2001010888A1 (fr) 2001-02-15
AU765983B2 (en) 2003-10-09
EP1181306A4 (fr) 2003-06-18
JP2003506071A (ja) 2003-02-18
AU5125300A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
AU765983B2 (en) Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
US5856445A (en) Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
AU722622B2 (en) BH3 interacting domain death agonist
WO1998009980A9 (fr) Agoniste de mort a domaine d'interaction bh3
US7709600B2 (en) Interaction between the VHL tumor suppressor and hypoxia inducible factor, and assay methods relating thereto
US7982002B2 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
WO1997037010A1 (fr) Domaines a activite de survie du recepteur du facteur i de croissance de type insulinique (igf-ir) et techniques d'utilisation
AU7344100A (en) Card proteins involved in cell death regulation
WO1998009643A1 (fr) Modulation de l'apoptoste par phophorylation de la serine du regulateur de mort cellulaire associe a bcl-xl/bcl-2
US7193044B1 (en) Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
US7579161B2 (en) Assay methods for suppressor of fused modulation of hedgehog signaling
AU779258B2 (en) Human suppressor of fused
US7041783B2 (en) Survivin-binding proteins, encoding nucleic acids, and methods of use
WO2002046219A2 (fr) Proteines d'activation de rho-gtpase et procedes correspondants
ZA200106937B (en) Human suppressor of fused.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued